Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSystem1 Group Regulatory News (SYS1)

Share Price Information for System1 Group (SYS1)

Share Price is delayed by 15 minutes
Get Live Data
325.00    -8.00 (-2.40%)
Bid:
320.00
Ask:
330.00
Spread: 10.00 (3.125%)
Market Cap: £41.24m
SYS1 Live PriceLast checked at - London Stock Exchange

Intraday System1 Group Share Chart

Trading Update

22 Oct 2025 07:00

RNS Number : 2929E
System1 Group PLC
22 October 2025
 

 

 

 

 

22 October 2025

 

 

System1 Group PLC (AIM: SYS1)

 ("System1", or "the Company", or "the Group")

Quarter 2 and Half Year Trading Update

 

 

 

Following the trading update on 23 September 2025, and ahead of today's capital markets webinar, System1, www.system1group.com issues an update on trading for the quarter ended 30 September 2025 (Q2 FY26) and the half-year ended 30 September 2025 (H1 FY26).

 

Revenue £ million* - unaudited

Q2

Q2

Q2

H1

H1

H1

FY26

FY25

% YoY

FY26

FY25

% YoY

Predict Your (data)

6.7

6.6

1%

13.4

13.4

1%

Improve Your (data-led consultancy)

1.3

1.6

-19%

2.8

3.3

-16%

Platform Revenue

7.9

8.1

-3%

16.2

16.7

-3%

Other consultancy (non-platform)

0.4

0.7

-45%

0.9

1.6

-46%

Total Revenue

8.3

8.9

-6%

17.1

18.3

-7%

 

*All numbers rounded to one decimal place. Percentages calculated from unrounded numbers.

 

Quarter 2

Platform Revenue decreased by 3% to £7.9m with data sales 1% higher and data-led consultancy 19% lower than in the same period last year. Platform Revenue comprised 95% of Total Group Revenue in Q2 FY26 (Q2 FY25: 92%). Total Q2 FY26 Revenue of £8.3m was 6% lower than Q2 FY25. As previously announced, the Company continued to see lower, but ongoing, spend from many of its largest clients, due to the wider macroeconomic uncertainty. New business flow remained strong in the quarter with wins including a multi-billion-dollar US beverage business, a global banking and wealth management company, the largest supermarket operator in the US, and the UK's largest wealth manager.

 

 

Half Year

New platform clients in H1 FY26 accounted for a record £3.4m of revenue. Platform Revenue in H1 FY26 fell by 3% versus H1 FY25 to £16.2m with data sales 1% higher and data-led consultancy 16% lower. Total H1 FY26 Revenue of £17.1m was 7% below the same period last year, including the impact of a £0.7m reduction in non-platform business. US Revenue continued to grow, up 3% (8% in USD). Innovation Revenue grew by 26% on the comparable period with Innovation platform revenue 107% higher, which was offset by lower ad-testing revenue. Revenue in continental Europe was 36% lower than in H1 FY25 despite improving quarter on quarter, and the UK trended broadly in line with the total company. Total Platform Revenue comprised 95% of Total Group Revenue in H1 FY26 (H1 FY25: 91%).

 

Gross Profit in H1 FY26 reached £14.9m at a margin of 87% (H1 FY25: £16m at 87% margin).

 

Operating expenditure increased by £0.9m (+7% on H1 FY25), due mainly to investment in growth over the past 18 months, with lower variable pay mitigating the year-on-year increase.

 

The cash balance at the end of H1 was £10.8m after the payment of all FY25 bonuses (end H1 FY25: £8.9m) and before the ca £1.4m dividend paid in October.

 

Full year guidance unchanged

Commenting on the trading update, CEO James Gregory said:

"We have made good progress in the focus areas of Innovation, the USA and winning with the world's largest brands - and this in the face of reduced market research spend by a number of our large clients. October is looking strong, and the Company continues to trade in line with the guidance1 we gave in the 23 September 2025 update"

 

Interim Results

The Company intends to release interim results for the half-year ended 30 September 2025 on 2 December 2025. Based on the unaudited management accounts, the Group expects to report an H1 Pre-Tax Adjusted Profit of £0.2 - £0.3 million for the half-year (H1 FY25: £2.5m).

 

1. Revenue for FY26 is expected to be broadly in line with the £37m achieved in FY25 and full year Adjusted PBT2 in a range between £2.0 to £2.5 million

2. Statutory Profit Before Taxation excluding share-based payment charges/credits

 

Further information on the Company can be found at www.system1group.com.

 

This announcement contains inside information for the purposes of article 7 of the Market Abuse Regulation (EU) 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310. With the publication of this announcement, this information is now considered to be in the public domain.

 

For further information, please contact:

System1 Group PLC

Tel: +44 (0)20 7043 1000

James Gregory, Chief Executive Officer

Chris Willford, Chief Financial Officer

 

Canaccord Genuity Limited (Nominated Adviser & Broker)

 

Tel: +44 (0)20 7523 8000

 

Simon Bridges / Andrew Potts / Harry Rees

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTPKDBPCBDDQKB
Date   Source Headline
1st May 20264:30 pmRNSHolding(s) in Company
21st Apr 20267:01 amRNSRelationship Agreement with Brave Bison
21st Apr 20267:00 amRNSQ4 and Full Year Trading Update
9th Apr 20267:00 amRNS-RLaunch of next evolution of Test Your Ad platform
30th Mar 20264:30 pmRNSHolding(s) in Company
30th Mar 20263:30 pmRNSDirector/PDMR Shareholding
16th Mar 20267:00 amRNSTrading Update
16th Mar 20267:00 amRNSTrading Update
5th Mar 20263:15 pmRNSDirector/PDMR Shareholding
3rd Mar 20265:15 pmRNSHolding(s) in Company
3rd Mar 20264:06 pmRNSBoard Change
2nd Mar 20261:39 pmRNSShareholder update & PDMR Dealing
2nd Mar 20267:00 amRNSDirectorate change
30th Jan 20261:00 pmRNSBoard Committee and Change of Role Update
20th Jan 20267:00 amRNSTrading Update
12th Jan 20264:45 pmRNSAppointment of Joint Corporate Broker
2nd Dec 20257:00 amRNSInterim Results
20th Nov 202511:45 amRNSHolding(s) in Company
24th Oct 20253:28 pmRNSHolding(s) in Company
22nd Oct 20257:00 amRNSTrading Update
14th Oct 20259:16 amRNSCapital Markets Day
6th Oct 20253:30 pmRNSDirector/PDMR Shareholding
30th Sep 20257:00 amRNSDirector/PDMR Shareholding - replacement
29th Sep 20255:48 pmRNSDirector/PDMR Shareholding
29th Sep 20251:27 pmRNSHolding(s) in Company
26th Sep 20252:29 pmRNSHolding(s) in Company
26th Sep 20257:00 amRNSDirector/PDMR Shareholding
24th Sep 20253:01 pmRNSResult of AGM
23rd Sep 20257:00 amRNSTrading Update
15th Sep 20251:00 pmRNSDirector/PDMR Shareholding
27th Aug 20254:51 pmRNSNotice of AGM
8th Aug 20254:35 pmRNSDirector/PDMR Shareholding
9th Jul 20257:00 amRNSDirector Role Change
9th Jul 20257:00 amRNSFinal Results
9th Jul 20257:00 amRNSTrading Update
4th Jul 202511:45 amRNSHolding(s) in Company
4th Jul 20257:00 amRNSHolding(s) in Company
16th Jun 20251:30 pmRNSHolding(s) in Company
14th May 20257:00 amRNSEstablishment of New Long-Term Incentive Plan
24th Apr 20251:53 pmRNSHolding(s) in Company
23rd Apr 20257:00 amRNSTrading Statement
23rd Jan 20257:00 amRNSHolding(s) in Company
21st Jan 20257:00 amRNSTrading Update
8th Jan 202510:15 amRNSHolding(s) in Company
3rd Dec 20247:00 amRNSInterim Results
28th Nov 20247:00 amRNSInterim Results Presentation
21st Nov 20243:31 pmRNSHolding(s) in Company
28th Oct 202410:15 amRNSDirector/PDMR Shareholding
23rd Oct 20247:00 amRNSDirector/PDMR Shareholding
22nd Oct 20247:00 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.